ArticleFrontiers in pharmacology2022

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.

Fenghao Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.